Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4.

Hepato-gastroenterology - 1 Jun 2015

El-Bendary Mahmoud, Neamatallah Mustafa A, Abd El-Maksoud Mohamed, Amin Maha

Abstract excerpt

BACKGROUND/AIMS: Egypt has the highest prevalence of HCV worldwide (15%) with a high morbidity and mortality from chronic liver disease, cirrhosis, and hepatocellular carcinoma. The Aim of this study was to investigate the associations between IL-28B single nucleotide polymorphisms (SNP rs12979860) and treatment outcome among Egyptian patients infected with HCV genotype 4. METHODOLOGY: HCV patients were genotyped...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Egypt

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferons

Share to Interleukins

Share to Logistic Models

Share to Polyethylene Glycols

Share to Real-Time Polymerase Chain Reaction

Share to Ribavirin

Source

Open in PubMed

Identifiers

PMID: 26902034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4.PMID 26902034Read ↗

Interleukin 28B polymorphisms and therapy response in Egyptian hepatitis C genotype-4 patients.Semantic proximity Read ↗

Is rs8099917 polymorphism of IL-28B gene a good predictor of response to therapy of HCV than rs12979860? An Egyptian study.Semantic proximity Read ↗

IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis.Semantic proximity Read ↗

Predictive power of Interleukin-28B gene variants for outcome of Hepatitis C Virus genotype 4 in Egyptians: A systematic review and meta-analysis.Semantic proximity Read ↗

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.Semantic proximity Read ↗

IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infectionSemantic proximity Read ↗

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.Semantic proximity Read ↗

Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.Semantic proximity Read ↗

Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients.Semantic proximity Read ↗

Impact of IL28B genetic variant's and viral genotype on treatment outcome of hepatitis C infected patients.Semantic proximity Read ↗

IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.Semantic proximity Read ↗

IL-28B rs12979860 polymorphism affect the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.